Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6589 台康生技. Please read: https://finlab.finance/en/setup?stock=6589

No install, open FinLab Studio

6589

台康生技 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, premium valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 台康生技 to your watchlist to track signal changes on your next visit.
Valuation 25Quality 8Growth 85Momentum 6Chips 5

Is 台康生技 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 4th market percentile. Latest quarterly ROE ≈ -1.7%.

  • Valuation is high.PE is in the 97th market percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -8.0% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 56.3%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral -0.13
BearishNeutralBullish

Institutional rotation, concentration steady — neutral

  • Institutional rotation, concentration steady — neutral
  • 美林 holds 1,154 lots
  • sellers have 589 lots left, ~380 sessions to clear

Window from 2026-01-17 · Price -30% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 美林 has accumulated 1,154 lots since the start (sold 14%), now trimming.
  • Main distributor 元大-永春 peaked at 351 lots, has sold 38%, 216 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders -1.99pp, mid holders -2, retail +1.11pp — drifting down to retail.
  • Foreign hedge-desk net short Net short -563 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
美林元大證券兆豐-復興凱基-台北國泰-新莊合庫-自強
Distributing
元大-永春國泰-台中玉山證券富邦-宜蘭凱基-中壢元大-成功
Desks
own scale
摩根大通富邦證券新加坡商瑞銀港商麥格理
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 美林 +1,154
    sold 14%
  • 元大證券 +975
    sold 0%· still adding
  • 兆豐-復興 +700
    sold 0%
  • 凱基-台北 +632
    sold 4%· still adding
  • 國泰-新莊 +517
    sold 12%
  • 合庫-自強 +461
    sold 16%

Distributing

  • 元大-永春 216 left
    sold 38%· paused recently
  • 國泰-台中 214 left
    sold 34%· ~67 sessions to clear
  • 玉山證券 151 left
    sold 38%· ~60 sessions to clear
  • 富邦-宜蘭 114 left
    sold 39%· ~380 sessions to clear
  • 凱基-中壢 35 left
    sold 59%· paused recently
  • 元大-成功 18 left
    sold 76%· paused recently

Desks

  • 摩根大通 -2,035
    hedge desk · will cover
  • 富邦證券 -1,368
    unclassified
  • 新加坡商瑞銀 -1,056
    hedge desk · will cover
  • 港商麥格理 -987
    hedge desk · will cover
Still selling 589 lots ~380 sessions to bottom at most
Recent buy/sell force +2,205 absorbed / -162 sold buyers slightly ahead
Hedge-desk net short -560 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 56.34%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

61 historical occurrences (since 2019-06-28)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 34.1%, Sample 44, Median -4.04%, Excess -1.74%, Beat mkt rate 29.5%；60-day: Win 37.2%, Sample 43, Median -5.36%, Excess -2.02%, Beat mkt rate 23.3%；120-day: Win 43.9%, Sample 41, Median -7.63%, Excess +9.95%, Beat mkt rate 31.7%

120 days after: historical avg +22.61%

20-day +0.75%
60-day +4.77%
120-day +22.61%
20-day
60-day
120-day
Win
34.1%
37.2%
43.9%
Sample
44
43
41
Median
-4.04%
-5.36%
-7.63%
Excess
-1.74%
-2.02%
+9.95%
Beat mkt rate
29.5%
23.3%
31.7%

Over 41 occurrences, 120-day forward avg gained 22.61%, beat the market by 9.95 pts; win rate 43.9%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

5 times historically; 60-day forward avg +16.64%, win rate 40%, beating the market by +8.12 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

21 times historically; 60-day forward avg -0.24%, win rate 28.6%, beating the market by -3.15 pts on average.

What does 台康生技 do? Company profile

生技醫療業 上市

Overview

6589 對應台康生技股份有限公司，為台灣證券交易所上市普通股；公司原為上櫃公司，2025-07-21 轉上市。公司成立於 2012-12-21，前身可追溯至生物技術開發中心蛋白質藥物先導工廠，總部位於新北市汐止區康寧街169巷101號，另有新竹縣竹北市生醫路一段168號之竹北廠及歐洲據點。董事長暨總經理為創辦人劉理成。Goodinfo 顯示資本額約新台幣30.69億元；官方年報前十大股東相互間關係表（2025-04-29）顯示主要股東包括鴻準精密工業27,500,000股、持股8.98%，永齡資本控股26,500,000股、8.65%，台耀化學18,552,818股、6.06%，行政院國家發展基金管理會15,288,860股、4.99%。公司汐止廠與竹北廠均具生物藥開發及生產能力；汐止廠定位為臨床前至前期臨床試驗及小量多樣生產，竹北廠定位為後期臨床至商業量產。已查來源未取得截至2026-06-17的完整員工人數，因此員工規模不填具體數字。

Business

台康生技採雙軌商業模式：一是生物藥品委託開發暨製造服務（CDMO），二是自有或合作產品開發，核心聚焦生物相似藥、利基型生物製劑、抗體藥物複合體（ADC）及蛋白質技術平台。CDMO服務涵蓋細胞株開發、製程開發與放大、分析方法開發與確效、蛋白質鑑定、品質檢驗、臨床試驗用藥及商業化生產；公司同時具備哺乳動物細胞與微生物發酵兩種表現系統。2024年營收結構依 MoneyDJ 資料為勞務收入59%、銷貨收入37%、授權合作開發收入4%；StockFeel 另列提供勞務59.3%、商品銷售26.9%、授權合作開發13.8%，兩來源口徑略有差異。主要產品管線包括 EG12014（Trastuzumab 生物相似藥，台灣商品名益康平 EIRGASUN，歐洲由 Sandoz 以 Herwenda 推廣）、EG1206A（Pertuzumab 生物相似藥）、EG12043/TSY0110（ADC，Kadcyla 相關生物相似藥方向）、EG13074、EG13084、EG12112、EG12164，以及 CRM197、HRV3C 等技術平台產品。EG12014已取得台灣150mg藥證及歐盟上市許可，台灣已進入醫學中心與區域醫院採購體系；Sandoz 擁有多數海外授權市場之商業化權利。CDMO客戶包括未具名日本藥廠長期供貨客戶及其他國內外生技、製藥公司；多數客戶名稱因保密未揭露。

Outlook 2025–2028

2025至2028年展望重點在三條主線。第一，EG12014 商業化進度：台灣市場150mg已上市並擴大醫院導入，420mg包裝已在台耀化學完成三批確效並推進台灣查驗登記與健保申請；歐洲 Herwenda 已於2023年取得上市許可，2025年完成製劑生產廠變更核准，2026年3月據 MoneyDJ 報導已於斯洛伐克完成市場准入並正式上市銷售，後續歐洲150mg與420mg放量是中期營收與分潤觀察重點；美國市場則為主要不確定性，EG12014曾多次收到 FDA CRL，問題主要集中於製造、充填或設施查核而非臨床、安全性或生物相似性本身，仍需視 Sandoz 與 FDA 互動及補件進展而定。第二，EG1206A（Pertuzumab 生物相似藥）被公司列為第二款重要研發產品，2025年法說資料顯示計畫2025年啟動三期臨床收案、2025至2026年完成三批原料藥及藥品確效批次，目標2027至2028年上市銷售；若順利，可切入 HER2 乳癌用藥市場，但仍有臨床、法規、授權與資金風險。第三，CDMO產能與服務模式升級：竹北商業化量產基地、汐止微生物廠及竹北大型微生物產能將支撐長約客戶與國際訂單，公司也表示將把生物相似藥逆向工程、CMC法規服務、製程確效與商業量產整合為一條龍CDMO服務，並評估海外CDMO併購標的。產業趨勢上，全球生物藥專利懸崖、生物相似藥成本壓力、各國供應鏈在地化與台灣健保對國產生物相似藥之鼓勵政策均屬正面因素；主要風險包括FDA查廠或補件延宕、歐美藥價與報銷壓力、臨床試驗失敗、授權里程碑收入波動、CDMO產能利用率不足、原物料與一次性耗材供應、匯率、資金需求與研發費用壓力。

Supply Chain

Upstream
  • 台耀化學股份有限公司 4746 台康主要股東之一，並與台康進行策略聯盟，合作發展抗體藥物複合體（ADC）；EG12014之420mg益康平凍晶注射劑確效批亦於台耀化學完成，屬製劑、充填或策略合作關係。
  • 南光化學製藥股份有限公司 1752 媒體報導曾稱為EG12014之冷凍乾燥充填協力廠商；與FDA CRL相關之歷史議題主要涉及藥品製造、充填或設施查核。此關係依媒體及歷史報導整理，需以公司最新公告為準。
  • 財團法人生物技術開發中心 未上市法人；台康前身與其蛋白質藥物先導工廠有關，亦曾列為主要股東，屬技術與設施承接來源之一。
  • 國際生物製程設備與耗材供應商 未具名供應商；台康製程使用一次性生物反應器、培養基、樹脂、緩衝液與分析檢驗耗材等，公開資料未完整揭露供應商名稱。
Downstream
  • Sandoz AG 瑞士上市或海外掛牌公司，非台股；台康EG12014主要海外授權與商業化夥伴，負責多數授權市場之Herwenda銷售，台康可收取簽約金、里程碑金及授權市場銷售分潤。
  • 日本合作藥廠 未揭露名稱；台康與日本藥廠簽訂長期供貨合約，供應即將或已於日本上市銷售之癌症病患輔助治療製劑相關原料藥，屬CDMO下游客戶。
  • 台灣醫學中心、區域醫院與地區醫院 非單一上市櫃公司；台康法說資料表示益康平EIRGASUN 150mg已進入台灣四大醫學中心系統及其他區域、地區醫院採購清單。
  • 國內外生技及製藥公司CDMO客戶 多數客戶未公開揭露；需求包括細胞株建立、製程開發、臨床用藥、商業量產、CMC法規服務與分析檢驗。

Competitors

Sources（20）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.